Browse > Article
http://dx.doi.org/10.4062/biomolther.2010.18.4.375

Targeting Multidrug Resistance with Small Molecules for Cancer Therapy  

Xia, Yan (Department of Medical Biotechnology, College of Life Science and Biotechnology, Dongguk University-Seoul)
Lee, Kyeong (Department of Medical Biotechnology, College of Life Science and Biotechnology, Dongguk University-Seoul)
Publication Information
Biomolecules & Therapeutics / v.18, no.4, 2010 , pp. 375-385 More about this Journal
Abstract
Conventional cancer chemotherapy is seriously limited by tumor cells exhibiting multidrug resistance (MDR), which is caused by changes in the levels or activity of membrane transporters that mediate energy-dependent drug efflux and of proteins that affect drug metabolism and/or drug action. Cancer scientists and oncologists have worked together for some time to understand anticancer drug resistance and develop pharmacological strategies to overcome such resistance. Much focus has been on the reversal of the MDR phenotype by inhibition of ATP-binding cassette (ABC) drug transporters. ABC transporters are a family of transporter proteins that mediate drug resistance and low drug bioavailability by pumping various drugs out of cells at the expense of ATP hydrolysis. Many inhibitors of MDR transporters have been identified, and though some are currently undergoing clinical trials, none are in clinical use. Herein, we briefly review the status of MDR in human cancer, explore the pathways of MDR in chemotherapy, and outline recent advances in the design and development of MDR modulators.
Keywords
Multidrug resistance; Chemotherapy; ATP-binding cassette;
Citations & Related Records
Times Cited By KSCI : 1  (Citation Analysis)
Times Cited By Web Of Science : 2  (Related Records In Web of Science)
Times Cited By SCOPUS : 1
연도 인용수 순위
1 Zaman, G. J. R., Versantvoort, C. H. M., Smit, J. J. M., Eijdems, E. W. H. M., De Haas, M., Smith, A. J., Broxterman, H. J., Mulder, N. H., De Vries, E. G. E., Baas, F. and Borst, P. (1993). Analysis of the expression of MRP, the gene for a new putative transmembrane drug transporter, in human multidrug resistant lung cancer cell lines. Cancer Res. 53, 1747-1750.
2 Toppmeyer, D., Seidman, A. D., Pollak, M., Russell, C., Tkaczuk, K., Verma, S., Overmoyer, B., Garg, V., Ette, E., Harding, M. W. and Demetri, G. D. (2002). Safety and efficacy of the multidrug resistance inhibitor Incel (biricodar; VX-710) in combination with paclitaxel for advanced breast cancer refractory to paclitaxel. Clin. Cancer Res. 8, 670-678.
3 Van Zanden, J. J., De Mul, A., Wortelboer, H. M., Usta, M., van Bladeren, P. J., Ivonne, M. C., Rietjens, M., Nicole, H. and Cnubben, P. (2005). Reversal of in vitro cellular MRP1 and MRP2 mediated vincristine resistance by the flavonoid myricetin. Biochem. Pharmacol. 69, 1657-1665.   DOI
4 Viale, M., Cordazzo, C., Cosimelli, B., de Totero, D., Castagnola, P., Aiello, C., Severi, E., Petrillo, G., Cianfriglia, M. and Spinelli, D. (2009). Inhibition of MDR1 activity in vitro by a novel class of diltiazem analogues: toward new candidates. J. Med. Chem. 52, 259-266.   DOI
5 Wada, M. (2006). Single nucleotide polymorphisms in ABCC2 and ABCB1 genes and their clinical impact in physiology and drug response. Cancer Letter 234, 40-50.   DOI
6 Weiss, J., Sauer, A., Frank, A. and Unger, M. (2005). Extracts and kavalactones of Piper methysticum G. Forst (kava-kava) inhibit P-glycoprotein in vitro. Drug Metab. Dispos. 33, 1580-1583.   DOI
7 Wu, C. P., Calcagno, A. M., Hladky, S. B., Ambudkar, S. V. and Barrand, M. A. (2005). Modulatory effects of plant phenols on human multidrug-resistance proteins 1, 4 and 5 (ABCC1, 4 and 5). FEBS J. 272, 4725-4740.   DOI
8 Xia, Y., Min, K. H. and Lee, K. (2009). Synthesis and Biological Evaluation of Decursin, Prantschimgin and Their Derivatives. Bull. Korean Chem. Soc. 30, 43-48.   DOI
9 Yu, S. T., Chen, T. M., Tseng, S. Y. and Chen, Y. H. (2007). Tryotanthrin inhibits MDR1 and reverses doxorubicin resistance in breast cancer cells. Biochem. Biophys. Res. Commun. 358, 79-84.   DOI
10 Romiti, N., Pellati, F., Nieri, P., Benvenuti, S., Adinolfi, B. and Chieli, E. (2008). P-glycoprotein inhibitory activity of lipophilic constituents of Echinacea pallida roots in a human proximal tubular cell lines. Planta Med. 74, 264-266.   DOI
11 Rowinsky, E. K., Smith, L., Wang, Y. M., Chaturvedi, P., Villalona, M., Campbell, E., Aylesworth, C., Eckhardt, S. G., Hammond, L., Kraynak, M., Drengler, R., Stephenson, J. J., Harding, M. W. and Von Hoff, D. D. (1998). Phase I and pharmacokinetic study of paclitaxel in combination with biricodar, a novel agent that reverses multidrug resistance conferred by overexpression of both MDR1 and MRP. J. Clin. Oncol. 16, 2964-2976.   DOI
12 Rubio, G. J., Pinedo, H. M., Gazdar, A. F., Van Ark-Otte, J. and Giaccone, G. (1994). MRP gene assessment in human cancer, normal lung, and lung cancer cell lines. Proc. Am. Assoc. Cancer Res. 35, 206.
13 Theis, J. G., Chan, H. S., Greenberg, M. L., Malkin, D., Karaskov, V., Moncica, I., Koren, G. and Doyle, J. (2000). Assessment of systemic toxicity in children receiving chemotherapy with cyclosporine for sarcoma. Med. Pediatr. Oncol. 34, 242-249.   DOI
14 Shukla, S., Wu, C. P., and Ambudkar, S. V. (2008). Development of inhibitors of ATP-binding cassette drug transporters - present status and challenges. Expert Opin. Drug Metab. Toxicol. 4, 205-223.   DOI
15 Skupien, K., Kostrzewa-Nowak, D., Oszmianski, J. and Tarasiuk, J. (2008). In vitro antileukemia activity of extracts from chokeberry (Aronia melanocarpa [Michx] Elliot) and mulberry (Morus alba L.) leaves against sensitive and multidrug resistant HL60 cells. Phytother. Res. 22, 689-694.   DOI
16 Takahashi, K., Kimura, Y., Nagata, K., Yamamoto, A., Matsuo, M. and Ueda, K. (2005). ABC proteins: key molecules for lipid homeostasis. Med. Mol. Morphol. 38, 2-12.   DOI
17 Thomas, H. and Coley, H. M. (2005). Overcoming multidrug resistance in cancer: an update on the clinical strategy of inhibiting p-glycoprotein. Cancer Control 10, 159-165.
18 Martelli, C., Coronnello, M., Dei, S., Manetti, D., Orlandi, F., Scapecchi, S., Romanelli, M. N., Salerno, M., Mini, E. and Teodori, E. (2010). Structure-activity relationships studies in a series of N,N-Bis(alkanol)amine aryl esters as P-Glycoprotein (Pgp) dependent multidrug resistance (MDR) inhibitors. J. Med. Chem. 53, 1755-1762.   DOI
19 Min, K. H., Xia, Y., Kim, E. K., Jin, Y. L., Kaur, N., Kim, E. S., Kim, D. K., Jung, H. Y., Choi, Y., Park, M. K., Min, Y. K., Lee, K. and Lee, K. (2009). A novel class of highly potent multidrug resistance reversal agents: Disubstituted adamantyl derivatives. Bioorg. Med. Chem. Lett. 19, 5376-5379.   DOI
20 Nakamura, M., Abe, Y., Katoh, Y., Oshika, Y., Hatanaka, H., Tsuchida, T., Yamazaki, H., Kijima, H., Inoue, H. and Ueyama, Y. (2000). A case of pulmonary adencarcinoma with overexpression of multidrug resistance associated protein and p53 aberration. Anticancer Res. 20, 1921-1925.
21 Newman, M. J., Rodarte, J. C., Benbatoul, K. D., Romano, S. J., Zhang, C., Krane, S., Moran, E. J., Uyeda, R. T., Dixon, R., Guns, E. S. and Mayer, L. D. (2000). Discovery and characterization of OC144-093, a novel inhibitor of P-glycoproteinmediated multidrug resistance. Cancer Res. 60, 2964-2972.
22 Pluen, A., Boucher, Y., Ramanujan, S., McKee, T. D., Gohongi, T., Tomaso, E., Brown, E. B., Izumi, Y., Campbell, R. B., Berk, D. A. and Jain, R. K. (2001). Role of tumor-host interactions in interstitial diffusion of macromolecules: cranial vs. subcutaneous tumors. Proc. Natl. Acad. Sci. 98, 4628-4633.   DOI
23 Polgar, O. and Bates, S. E. (2004). ABC transporters in the balance: is there a role in multidrug resistance? Biochem. Soc. Trans. 33, 241-245.   DOI
24 Raad, I., Terreux, R., Richomme, P., Matera, E. L., Dumontet, C., Raynaud, J. and Guilet, D. (2006). Structure- activity relationship of natural and synthetic coumarins inhibiting the multidrug transporter P-glycoprotein. Bioorg. Med. Chem. 14, 6979-6987.   DOI
25 Kuhnle, M., Egger, M., Muller, C., Mahringer, A., Bernhardt, G., Fricker,G., Konig, B. and Buschauer, A. (2009). Potent and selective inhibitors of breast cancer resistance protein (ABCG2) derived from the P-Glycoprotein (ABCB1) modulator tariquidar. J. Med. Chem. 52, 1190-1197.   DOI
26 Leonard, G. D., Fojo, T. and Bates, S. E. (2003). The role of ABC transporters in clinical practice. Oncologist 8, 411-424.   DOI
27 Li, Y., Zhang, H. B. and Huang, W. L. (2008). Design and synthesis of tetrahydroisoquinoline derivatives as potential multidrug resistance reversal agents in cancer. Bioorg. Med. Chem. Lett. 18, 3652-3655.   DOI
28 Limtrakul, P., Siwanon, S., Yodkeeree, S. and Duangrat, C. (2007b). Effect of Stemona curtisii root extract on P-glycoprotein and MRP-1 function in multidrug-resistant cancer cells. Phytomedicine 14, 381-389.   DOI
29 Limtrakul, P. (2007). Curcumin as chemosensitizer. Adv. Exp. Med. Biol. 595, 269-300.   DOI
30 Limtrakul, P., Chearwae, W., Shukla, S., Phisalphong, C. and Ambudkar, S. V. (2007a). Modulation of function of three ABC transporters, P-glycoprotein (ABCB1), mitoxanthrone resistance protein (ABCG2) and multidrug resistance protein 1 (ABCC1) by tetrahydrocurcumin, a major metabolite of curcumin. Mol. Cell Biochem. 296, 85-95.   DOI
31 Liscovitch, M. and Lavie, Y. (2002). Cancer multidrug resistance: a review of recent drug discovery research. Drugs 5, 349-355.
32 Liu, D. F., Li, Y. P., Ou, T. M., Huang, S. L., Gu, L. Q., Huang, M. and Huang, Z. S. (2009). Synthesis and antimultidrug resistance evaluation of icariin and its derivatives. Bioorg. Med. Chem. Lett. 19, 4237-4240.   DOI
33 Longley, D. B. and Johnston, P. G. (2005). Molecular mechanisms of drug resistance. J. Pathol. 205, 275-292.   DOI
34 Henrich, C. J., Bokesch, H. R., Dean, M., Bates, S. E., Robey, R. W., Goncharova, E. I., Wilson, J. A. and McMahon, J. B. (2006). A high-throughput cell-based assay for inhibitors of ABCG2 activity. J. Biomol. Screen 11, 176-183.   DOI
35 Jin, J., Wang, F. P., Wei, H. and Liu, G. (2005). Reversal of multidrug resistance of cancer through inhibition of Pglycoprotein by 5-bromotetrandrine. Cancer Chemother. Pharmacol. 55, 179-188.   DOI
36 Kim, R. B., Wandel, C., Leake, B., Cvetkovic, M., Fromm, M. F., Dempsey, P. J., Roden, M. M., Belas, F., Chaudhary, A. K., Roden, D. M., Wood, A. J. and Wilkinson, G. R. (1999). Interrelationship between substrates and inhibitors of human CYP3A and P-glycoprotein. Pharm. Res. 16, 408-414.   DOI
37 Katayama, K., Masuyama, K., Yoshioka, S., Hasegawa, H., Mitsuhashi, J. and Sugimoto, Y. (2007). Flavonoids inhibit breast cancer resistance protein-mediated drug resistance: transporter specificity and structure-activity relationship. Cancer Chemother. Pharmacol. 60, 789-797.   DOI
38 Kellen, J. A. (2003). The reversal of multidrug resistance: an update. J. Exp. Ther. Oncol. 3, 5-13.   DOI
39 Kim, D. H., Park, J. Y., Sohn, S. K., Lee, N. Y., Baek, J. H., Jeon, S. B., Kim, J. G., Suh, J. S., Do, Y. R. and Lee, K. B. (2006). Multidrug resistance-1 gene polymorphisms associated with treatment outcomes in de novo acute myeloid leukemia. Int. J. Cancer 118, 2195-2201.   DOI
40 Krishna, R. and Mayer, L. D. (2000). Multidrug resistance (MDR) in cancer. Mechanisms, reversal using modulators of MDR and the role of MDR modulators in influencing the pharmacokinetics of anticancer drugs. Eur. J. Pharm. Sci. 11, 265-283.   DOI
41 Krug, M., Voigt, B., Baumert, C., Lupken, R., Molnar, J. and Hilgeroth, A. (2010). First biological evaluation of developed 3-benzyloxyfluorenes as novel class of MDR modulators. Eur. J. Med. Chem. 45, 2683-2688   DOI
42 Gottesman, M. M. (2002). Mechanisms of cancer drug resistance. Annu. Rev. Med. 53, 615-627.   DOI
43 Gottesman, M. M., Fojo, T. and Bates, S. E. (2002). Multidrug resistance in cancer: role of ATP-dependent transporters. Nature Reviews Cancer 2, 48-58.   DOI
44 Hacker, H. G., Leyers, S., Wiendlocha, J., Gutschow, M. and Wiese, M. (2009b). Aromatic 2-(Thio)ureidocarboxylic acids as a new family of modulators of multidrug resistanceassociated protein 1: synthesis, biological evaluation, and structure-activity relationships. J. Med. Chem. 52, 4586- 4595.   DOI
45 Gottesman, M. M. and Pastan, I. (1996). Drug resistance: alterations in drug uptake or extrusion. In Encyclopedia of Cancer (J. R. Bertino, Ed.) pp. 549-559. Academic, San Diego, CA.
46 Gruber, A., Bjorkholm, M., Brinch, L., Evensen, S., Gustavsson, B., Hedenus, M., Juliusson, G., Löfvenberg, E., Nesthus, I., Simonsson, B., Sjo, M., Stenke, L., Tangen, J. M., Tidefelt, U., Udén, A. M., Paul, C. and Liliemark, J. (2003). A phase I/II study of the MDR modulator Valspodar (PSC 833) combined with daunorubicin and cytarabine in patients with relapsed and primary refractory acute myeloid leukemia. Leuk. Res. 27, 323-328.   DOI
47 Hacker, H. G., de la Haye, A., Sterz, K., Schnakenburg, G., Wiese, M. and Gutschow, M. (2009a). Analogs of a 4-aminothieno[2,3-d]pyrimidine lead (QB13) as modulators of P-glycoprotein substrate specificity. Bioorg. Med. Chem. Lett. 19, 6102-6105.   DOI
48 Hao, X. Y., Widersten, M., Ridderstrom, M., Hellman, U. and Mannervik, B. (1994). Covariation of glutathione transferase expression and cytostatic drug resistance in HeLa cells: establishment of class Mu glutathione transferase M3-3 as the dominating isoenzyme. Biochem. J. 297, 59-67.   DOI
49 Jin, J., Shahi, S., Kang, H. K., Van Veen, H. W. and Fan, T. P. (2006). Metabolism of ginsenosides as novel BCRP inhibitors. Biochem. Biophys. Res. Commun. 345, 1308-1314.   DOI
50 Dantzig, A. H., Shepard, R. L., Law, K. L., Tabas, L., Pratt, S., Gillespie, J. S., Binkley, S. N., Kuhfeld, M. T., Starling, J. J. and Wrighton, S. A. (1999). Selectivity of the multidrug resistance modulator, LY335979, for P-glycoprotein and effect on cytochrome P-450 activities. J. Pharmacol. Exp. Ther. 290, 854-862.
51 Efferth, T. (2001). The human ATP-binding cassette transporter genes: from the bench to the bedside. Curr. Mol. Med. 1, 45-65.   DOI
52 Das, U., Molnár, J., Bará th, Z., Bata, Z. and Dimmock, J. R. (2008). 1-[4-(2-Aminoethoxy)phenylcarbonyl]-3,5-bis (benzylidene)- 4-oxopiperidines: a novel series of highly potent revertants of P-glycoprotein associated multidrug resistance. Bioorg. Med. Chem. Lett. 18, 3484-3487.   DOI
53 Dean, M., Rzhetsky, A. and Allikmets, R. (2001). The human ATP-binding cassette (ABC) transporter superfamily. Genome Res. 11, 1156-1166.   DOI
54 Demant, E. J., Sehested, M. and Jensen, P. B. (1990). A model for computer simulation of P-glycoprotein and transmembrane delta pH-mediated anthracycline transport in multidrug resistant tumor cells. Biochim. Biophys. Acta. 1055, 117-125.   DOI
55 Fan, D., Beltran, P. J. and O’Brien, C. A. (1994). Reversal of multidrug resistance. In Reversal of Multidrug Resistance in Cancer (J. A. Kellen, Ed.), pp. 93-124. CRC Press, Boca Raton, FL.
56 Fong, W. F., Shen, X. L., Globisch, C., Wiese, M., Chen, G. Y., Zhu, G. Y., Yu, Z. L., Tse, A. K. W. and Hue, Y. J. (2008). Methoxylation of 3’,4’-aromatic side chains improves P-glycoprotein inhibitory and multidrug resistance reversal activities of 7,8-pyranocoumarin against cancer cells. Bioorg. Med. Chem. 16, 3694-3703.   DOI
57 Ford, J. M. and Hait, W. N. (1990). Pharmacology of drugs that alter multidrug resistance in cancer. Pharmacol. Rev. 42, 155-199.
58 Garcia, M., Jemal, A., Ward, E. M., Center, M. M., Hao, Y., Siegel, R. L. and Thun, M. J. (2007). Global Cancer Facts and Figures 2007. American Cancer Society, Atlanta, GA.
59 Chearwae, W., Wu, C. P., Chu, H. Y., Lee, T. R., Ambudkar, S. V. and Limtrakul, P. (2006). Curcuminoids purified from tumeric powder modulate the function of human multidrug resistance protein 1 (ABCC1). Cancer Chemother. Pharmacol. 57, 376-388.   DOI
60 Broxterman, H. J., Kuiper, C. M., Schuurhuis, G. J., Ossen koppele, G. J., Feller, N., Scheper, R. J., Lankelma, J. and Pinedo, H. M. (1994). Analysis of P-glycoprotein (P-gp) and non-P-gp multidrug resistance in acute myeloid leukemia. Proc. Am. Assoc. Cancer Res. 35, 348.
61 Choi, C. H. (2005). ABC transporters as multidrug resistance mechanisms and the development of chemosensitizers for their reversal. Cancer Cell Int. 5, 30.   DOI
62 Coburger, C., Wollmann, J., Baumert, C., Krug, M., Molna´r, J., Lage, H. and Hilgeroth, A. (2008). Novel insight in structureactivity relationship and bioanalysis of P-Glycoprotein targeting highly potent tetrakishydroxymethyl substituted 3,9- Diazatetraasteranes. J. Med. Chem. 51, 5871-5874.   DOI
63 Colabufo, N. A., Berardi, F., Cantore, M., Perrone, M. G., Contino, M., Inglese, C., Niso, M., Perrone, R., Azzariti, A., Simone, G. M., Porcelli, L. and Paradiso, A. (2008a). Small P-gp modulating molecules: SAR studies on tetrahydroisoquinoline derivatives. Bioorg. Med. Chem. 16, 362-373.
64 Colabufo, N. A., Berardi, F., Perrone, R., Rapposelli, S., Digiacomo, M., Vanni, M. and Balsamo, A. (2008b). Synthesis and biological evaluation of (Hetero) arylmethyloxy- and arylmethylamine- phenyl derivatives as potent P-glycoprotein modulating agents. J. Med. Chem. 51, 1415-1422.   DOI
65 Colabufo, N. A., Berardi, F., Perrone, R., Rapposelli, S., Digiacomo, M., Vanni, M. and Balsamo, A. (2008c). 2-[(3-Methoxyphenylethyl) phenoxy]-based ABCB1 Inhibitors: effect of different basic side-chains on their biological properties. J. Med. Chem. 51, 7602-7613.   DOI
66 Anderle, P., Huang, Y. and Sadee, W. (2004). Intestinal membrane transport of drugs and nutrients: Genomics of membrane transporters using expression microarrays. Eur. J. Pharm. Sci. 21, 17-24.   DOI
67 Abolhoda, A., Wilson, A. E., Ross, H., Denenberg, R. V., Burt, M. and Scotto, K. W. (1999). Rapid activation of MDR1 gene expression in human metastatic sarcoma after in vivo exposure to doxorubicin. Clin. Cancer Res. 5, 3352-3356.
68 Almquist, K. C., Loe, D. W., Hipfner, D. R., Mackie, J. E., Cole, S. P. and Deeley, R. G. (1995). Characterization of the M 190 000 multidrug resistance protein (MRP) in drug selected and transfected human tumor cell. Cancer Res. 55, 102-110.
69 Ambudkar, S. V., Dey, S., Hrycyna, C. A., Ramachandra, M., Pastan, I. and Gottesman, M. M. (1999). Biochemical, cellular and pharmacological aspects of the multidrug transporter. Annu. Rev. Pharmacol. Toxicol. 34, 361-398.
70 Beck, J., Gekeler, V., Handgretinger, R. and Niethammer, D. (1994). PCR gene expression analysis of multidrug resistance associated genes in primary and relapsed state leukemias: comparison of mdrl, mrp, topoisomerase IIa, topoisomerase IIb and cyclin A mRNA levels. Proc. Am. Assoc. Cancer Res. 35, 337.
71 Benet, L. Z. and Cummins, C. L. (2001). The drug efflux- metabolism alliance: biochemical aspects. Adv. Drug Deliv. Rev. 50(Suppl 1), S3-S11.   DOI
72 Borst, P., Evers, R., Kool, M. and Wijnholds, J. (2000). A family of drug transporters: the multidrug resistance-associated proteins. J. Natl. Cancer Inst. 92, 1295-302.   DOI
73 Borst, P., Kool, M. and Evers, R. (1997). Do cMOAT (MRP2), other MRP homologues, and LRP play a role in MDR. Cancer Biol. 8, 205-213.   DOI